Clorox Beats Q4 Estimates, Sees Full-Year Sales Boost from Purell Deal
CLX sits 16% above its 52-week low of $84.7.
Summary
Clorox beat analyst expectations in Q4 despite declining volumes and higher costs. The company also said the recent GOJO/Purell acquisition should lift full-year sales. This positive surprise and upbeat outlook contrast with the earlier earnings report that highlighted a 51% profit plunge and disappointing guidance. The Purell deal appears to be a key growth driver, and the beat suggests underlying resilience. Watch for management commentary on the earnings call for details on the sales boost and cost pressures.
At the time of this announcement, CLX was trading at $98.63 on NYSE in the Trade & Services sector, with a market capitalization of approximately $11.9B. The 52-week trading range was $84.70 to $128.90. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Binance News.